Table 3

Expected results of the base case cost-effectiveness analysis

PerspectiveStrategyCostΔCostUtility (QALYs)ΔUtilityICER* ($/QALY)
SocietalStandard care$11 42813.13
Risk-stratified prevention
 Braden <10 (very high risk)$11 410−$1813.160.03Dominant
 Braden <13 (very high and high risk)$11 406−$2213.160.03Dominant
 Braden <15 (very high, high and moderate risk)$11 404−$2413.190.06Dominant
 Braden <19 (very high, high, moderate and at risk)$11 484$5613.220.09$622
Prevention-for-all$11 668$24013.250.12$2000
Health sectorStandard care$10 78613.13
Risk-stratified prevention
 Braden <10 (very high risk)$10 768−$1813.160.03Dominant
 Braden <13 (very high and high risk)$10 763−$2313.160.03Dominant
 Braden <15 (very high, high and moderate risk)$10 761−$2513.190.06Dominant
 Braden <19 (very high, high, moderate  and at risk)$10 842$5613.220.09$622
Prevention-for-all$11 025$25713.250.12$2142
  • *ICER=(costa–costb)/(utilitya–utilityb); a ‘Dominant’ ICER refers to option ‘a’ being preferred to option ‘b’ based on resulting in a greater utility at lower cost, ie, cost saving.

  • ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.